ACR Meeting Abstracts

ACR Meeting Abstracts

  • Meetings
    • ACR Convergence 2024
    • ACR Convergence 2023
    • 2023 ACR/ARP PRSYM
    • ACR Convergence 2022
    • ACR Convergence 2021
    • ACR Convergence 2020
    • 2020 ACR/ARP PRSYM
    • 2019 ACR/ARP Annual Meeting
    • 2018-2009 Meetings
    • Download Abstracts
  • Keyword Index
  • Advanced Search
  • Your Favorites
    • Favorites
    • Login
    • View and print all favorites
    • Clear all your favorites
  • ACR Meetings

Abstract Number: 1895

Correlation of Scleroderma Interstitial Lung Disease with Gastroesophageal Reflux

Brady Bulian1, W Leroy Griffing2 and Michael Crowell3, 1Internal Medicine, Mayo Clinic Arizona, Scottsdale, AZ, 2Rheumatology, Mayo Clinic Arizona, Scottsdale, AZ, 3Gastroenterology, Mayo Clinic Arizona, Scottsdale, AZ

Meeting: 2015 ACR/ARHP Annual Meeting

Date of first publication: September 29, 2015

Keywords: Scleroderma

  • Tweet
  • Click to email a link to a friend (Opens in new window) Email
  • Click to print (Opens in new window) Print
Session Information

Date: Monday, November 9, 2015

Title: Systemic Sclerosis, Fibrosing Syndromes and Raynaud's - Clinical Aspects and Therapeutics Poster II

Session Type: ACR Poster Session B

Session Time: 9:00AM-11:00AM

Background/Purpose: Systemic sclerosis (SSc)
is a connective tissue disease involving the skin and visceral organs, most
commonly the gastrointestinal tract and lungs.  Interstitial lung disease
(ILD) is present in up to 75% of cases and is the leading cause of mortality in
SSc.  Recent studies have shown a correlation
between gastroesophageal reflux (GER) and SSc-ILD,
however, doubt remains regarding the extent to which GER affects ILD.  In this study we compared GER, esophageal
dysmotility and lower esophageal sphincter (LES) tone
in those with and without ILD, hypothesizing that the presence and extent of
esophageal involvement would correlate with presence and extent of ILD.

Methods: A retrospective review identified
thirty-nine patient cases of SSc that met diagnostic
criteria as set by the American College of Rheumatology.   Data were
collected from high-resolution computed tomography (HRCT), pulmonary function
testing (PFT), esophageal pH-Impedance testing (pH-I) and high-resolution
esophageal manometry (HREM) to assess GER, esophageal dysmotility and lower
esophageal sphincter tone in those with and without ILD.  Significant GER was defined as DeMeester
score > 14.72 on pH-I and Goh criteria3 were used to stage ILD as
limited or extensive.

Results: The ILD and non-ILD groups were similar
in regards to sex, age, disease duration or modified Rodnan skin score.  Patients with ILD had higher rates of
significant GER at 75% vs. 33% of controls (p = 0.01).  The ILD group also had higher rates of absent
peristalsis at 100% vs. 59% (p = 0.009) and hypotensive LES at 92% vs.
70% (p = 0.13).  In subgroup
analysis of those with extensive ILD vs. limited ILD, 83% vs. 50% had
significant GER (p = 0.19).  These results are listed below in Table 1.

Table 1.  Demographics and data of ILD (N=12) vs. non-ILD (N=27) groups and Extensive ILD3 (N=6) vs. Limited ILD3 groups (N=6). (mean ± SD)

Demographics

ILD  

Non-ILD  

       Age (years)

56.71 ± 11.95

58.50 ±12.72            p = 0.67

       Sex (male)

17% (2 of 12)

11% (3 of 27)           p = 0.62

       SSc duration1 (years)

10.07 ± 8.89

5.58 ± 4.25               p = 0.11

       MRSS

14.15 ± 12.81

21.00 ± 12.04           p = 0.14

Data

       Significant GER2

75 % (8 of 12)

33% (9 of 27)           p = 0.01

       Average DeMeester

43.35 ± 38.92

29.66 ± 56.47           p = 0.45

       Absent peristalsis

100% (12 of 12)

59% (16 of 27)         p = 0.009

       Hypotensive LES

92% (11 of 12)

70% (19 of 27)         p = 0.13

Extensive ILD3 

Limited ILD3  

       Significant GER2

83% (5 of 6)

50% (3 of 6)              p = 0.19

   Average DeMeester

49.83 ± 43.74

36.87 ± 36.31            p = 0.59

Abbreviations: ILD = Interstitial lung disease. SSc = Systemic sclerosis. MRSS = Modified Rodnan Skin Score.  GER = Gastroesophageal reflux. LES = Lower esophageal sphincter. 1: Defined by first onset of non-Raynaud’s phenomenon SSc feature. 2: Determined as DeMeester score greater than 14.72 on pH-Impedance testing. 3: As outlined by Goh N.S., et al. Interstitial lung disease in systemic sclerosis: a simple staging system. AJRCCM. 177, 1248-1254 (2008). 

Conclusion: We report a statistically significant
positive correlation between SSc-ILD and the presence
of significant GER or esophageal dysmotility, with a trend toward extensive ILD
in those with more severe GER.  These findings support the notion that GER
likely contributes to the development and progression of SSc-ILD,
and that aggressive medical or surgical treatment of GER is warranted to
decrease the morbidity and mortality associated with ILD.


Disclosure: B. Bulian, None; W. L. Griffing, None; M. Crowell, None.

To cite this abstract in AMA style:

Bulian B, Griffing WL, Crowell M. Correlation of Scleroderma Interstitial Lung Disease with Gastroesophageal Reflux [abstract]. Arthritis Rheumatol. 2015; 67 (suppl 10). https://acrabstracts.org/abstract/correlation-of-scleroderma-interstitial-lung-disease-with-gastroesophageal-reflux/. Accessed .
  • Tweet
  • Click to email a link to a friend (Opens in new window) Email
  • Click to print (Opens in new window) Print

« Back to 2015 ACR/ARHP Annual Meeting

ACR Meeting Abstracts - https://acrabstracts.org/abstract/correlation-of-scleroderma-interstitial-lung-disease-with-gastroesophageal-reflux/

Advanced Search

Your Favorites

You can save and print a list of your favorite abstracts during your browser session by clicking the “Favorite” button at the bottom of any abstract. View your favorites »

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].

Wiley

  • Online Journal
  • Privacy Policy
  • Permissions Policies
  • Cookie Preferences

© Copyright 2025 American College of Rheumatology